Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Apr 20  •  04:00PM ET
10.73
Dollar change
-0.01
Percentage change
-0.09
%
Index
-
P/E
-
EPS (ttm)
-0.02
Insider Own
-
Shs Outstand
334.13M
Perf Week
-4.54%
Market Cap
3.64B
Forward P/E
90.19
EPS next Y
0.12
Insider Trans
-
Shs Float
-
Perf Month
25.20%
Enterprise Value
3.96B
PEG
-
EPS next Q
0.02
Inst Own
0.33%
Perf Quarter
38.27%
Income
-7.13M
P/S
4.52
EPS this Y
306.33%
Inst Trans
7.08%
Perf Half Y
-1.20%
Sales
804.63M
P/B
8.75
EPS next Y
173.27%
ROA
-0.67%
Perf YTD
43.26%
Book/sh
1.23
P/C
25.65
EPS next 5Y
-
ROE
-1.86%
52W High
20.00 -46.35%
Perf Year
-35.79%
Cash/sh
0.42
P/FCF
-
EPS past 3/5Y
55.05% 29.38%
ROIC
-0.83%
52W Low
6.28 70.86%
Perf 3Y
-
Dividend Est.
-
EV/EBITDA
101.15
Sales past 3/5Y
93.54% 195.21%
Gross Margin
53.15%
Volatility
2.94% 3.23%
Perf 5Y
-
Dividend TTM
-
EV/Sales
4.93
EPS Y/Y TTM
-121.18%
Oper. Margin
2.20%
ATR (14)
0.41
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
1.27
Sales Y/Y TTM
55.73%
Profit Margin
-0.89%
RSI (14)
68.95
Dividend Gr. 3/5Y
- -
Current Ratio
1.43
EPS Q/Q
-
SMA20
9.76%
Beta
-0.11
Payout
-
Debt/Eq
1.12
Sales Q/Q
-
SMA50
29.14%
Rel Volume
0.57
Prev Close
10.74
Employees
-
LT Debt/Eq
1.08
SMA200
9.26%
Avg Volume
265.55K
Price
10.73
IPO
Nov 14, 2024
Option/Short
No / Yes
Trades
Volume
189,377
Change
-0.09%
Date Action Analyst Rating Change Price Target Change
Sep-18-25Initiated Citigroup Buy $22
Aug-28-25Downgrade JP Morgan Overweight → Neutral
Jul-03-25Initiated H.C. Wainwright Buy $23
Jun-05-25Initiated Wedbush Outperform $22
Nov-15-24Initiated UBS Buy $21
Apr-14-26 07:04PM
04:34AM
Apr-13-26 06:30AM
Apr-09-26 06:51PM
Apr-08-26 06:44PM
07:37PM Loading…
Apr-06-26 07:37PM
Apr-01-26 07:53PM
Mar-15-26 05:25PM
Mar-10-26 07:01AM
Mar-09-26 07:19PM
Mar-01-26 10:33PM
05:57PM
Feb-27-26 07:00AM
03:40AM
Feb-20-26 08:32AM
07:00AM Loading…
07:00AM
12:55AM
12:04AM
Feb-19-26 11:08PM
07:02PM
Feb-17-26 04:55PM
Feb-03-26 04:35PM
Jan-21-26 02:15PM
Jan-20-26 07:00AM
Jan-16-26 02:19PM
Jan-09-26 03:16AM
Jan-08-26 06:00AM
Jan-06-26 09:00AM
Dec-29-25 02:41AM
Dec-21-25 04:38PM
05:23AM Loading…
Dec-18-25 05:23AM
Dec-16-25 03:30PM
Dec-15-25 12:34PM
Dec-10-25 07:00AM
Dec-08-25 04:01PM
Dec-05-25 03:30PM
Dec-01-25 07:06PM
Nov-28-25 05:25PM
Nov-25-25 08:03PM
08:45AM
Nov-19-25 02:00PM
Nov-18-25 03:03PM
Nov-13-25 08:25AM
Nov-11-25 05:36PM
Nov-05-25 06:00AM
Oct-23-25 07:00AM
Oct-22-25 04:00PM
Oct-14-25 02:22AM
Sep-30-25 04:12AM
Sep-23-25 10:15AM
Sep-18-25 10:40AM
Sep-16-25 09:47AM
Sep-09-25 07:00PM
Aug-26-25 07:00AM
Aug-20-25 08:22PM
05:23AM
04:36AM
Jul-29-25 06:58PM
Jul-22-25 04:39AM
04:06AM
Jul-09-25 06:45PM
Jul-03-25 09:41AM
Jun-29-25 01:28PM
Jun-25-25 04:04AM
Jun-23-25 07:15AM
Jun-20-25 08:00AM
Jun-19-25 08:18PM
Jun-13-25 04:35AM
Jun-11-25 07:00AM
Jun-05-25 02:15AM
Jun-04-25 12:55AM
Jun-03-25 06:30PM
06:57AM
May-22-25 08:00AM
May-19-25 06:00PM
May-12-25 07:22PM
May-07-25 04:13PM
May-05-25 04:55AM
Apr-30-25 02:17AM
Apr-28-25 06:30PM
Apr-22-25 04:17AM
Apr-15-25 07:04PM
02:16AM
Apr-14-25 12:00PM
Apr-09-25 01:30PM
Apr-08-25 06:30AM
Apr-07-25 06:30AM
Apr-06-25 07:09PM
Apr-05-25 01:03AM
Apr-03-25 06:13PM
Apr-01-25 03:30PM
08:49AM
Mar-23-25 12:00PM
Mar-21-25 10:40AM
06:30AM
Mar-20-25 08:38PM
Mar-17-25 07:37PM
Mar-12-25 07:11PM
Mar-03-25 04:48PM
Feb-25-25 08:01PM
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Darren CharltonGroup Chief Financial OfficerMar 29 '26Option Exercise0.001,111011,921Apr 01 07:14 PM